vs

Side-by-side financial comparison of Fortress Biotech, Inc. (FBIO) and Red Cat Holdings, Inc. (RCAT). Click either name above to swap in a different company.

Fortress Biotech, Inc. is the larger business by last-quarter revenue ($16.1M vs $9.6M, roughly 1.7× Red Cat Holdings, Inc.). Fortress Biotech, Inc. runs the higher net margin — -24.5% vs -166.0%, a 141.5% gap on every dollar of revenue. On growth, Red Cat Holdings, Inc. posted the faster year-over-year revenue change (988.2% vs 6.3%).

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

Mega Cat Studios is an American video game development and publishing company located in Pittsburgh, Pennsylvania. It was founded in 2015 by James Deighan, Nick Mann, and Zack Manko.

FBIO vs RCAT — Head-to-Head

Bigger by revenue
FBIO
FBIO
1.7× larger
FBIO
$16.1M
$9.6M
RCAT
Growing faster (revenue YoY)
RCAT
RCAT
+982.0% gap
RCAT
988.2%
6.3%
FBIO
Higher net margin
FBIO
FBIO
141.5% more per $
FBIO
-24.5%
-166.0%
RCAT

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FBIO
FBIO
RCAT
RCAT
Revenue
$16.1M
$9.6M
Net Profit
$-3.9M
$-16.0M
Gross Margin
66.1%
6.6%
Operating Margin
-28.8%
-181.7%
Net Margin
-24.5%
-166.0%
Revenue YoY
6.3%
988.2%
Net Profit YoY
41.8%
-29.0%
EPS (diluted)
$-0.15
$-0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FBIO
FBIO
RCAT
RCAT
Q4 25
$16.1M
Q3 25
$17.6M
$9.6M
Q2 25
$16.4M
Q1 25
$13.1M
$1.6M
Q4 24
$15.1M
$0
Q3 24
$14.6M
Q2 24
$14.9M
Q1 24
$13.0M
$5.8M
Net Profit
FBIO
FBIO
RCAT
RCAT
Q4 25
$-3.9M
Q3 25
$5.8M
$-16.0M
Q2 25
$15.5M
Q1 25
$-10.6M
$-23.1M
Q4 24
$-6.8M
$-13.3M
Q3 24
$-12.9M
Q2 24
$-10.9M
Q1 24
$-15.4M
$-5.5M
Gross Margin
FBIO
FBIO
RCAT
RCAT
Q4 25
66.1%
Q3 25
67.4%
6.6%
Q2 25
69.9%
Q1 25
63.5%
-52.2%
Q4 24
69.1%
Q3 24
69.4%
Q2 24
61.6%
Q1 24
53.9%
18.8%
Operating Margin
FBIO
FBIO
RCAT
RCAT
Q4 25
-28.8%
Q3 25
-38.6%
-181.7%
Q2 25
-222.2%
Q1 25
-169.9%
-765.7%
Q4 24
-158.3%
Q3 24
-151.0%
Q2 24
-186.5%
Q1 24
-280.6%
-76.0%
Net Margin
FBIO
FBIO
RCAT
RCAT
Q4 25
-24.5%
Q3 25
33.2%
-166.0%
Q2 25
94.4%
Q1 25
-80.6%
-1418.9%
Q4 24
-44.7%
Q3 24
-88.0%
Q2 24
-73.5%
Q1 24
-118.3%
-93.9%
EPS (diluted)
FBIO
FBIO
RCAT
RCAT
Q4 25
$-0.15
Q3 25
$0.11
$-0.16
Q2 25
$0.45
Q1 25
$-0.48
$-0.27
Q4 24
$-0.16
Q3 24
$-0.76
Q2 24
$-0.73
Q1 24
$-1.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FBIO
FBIO
RCAT
RCAT
Cash + ST InvestmentsLiquidity on hand
$79.4M
Total DebtLower is stronger
$52.4M
Stockholders' EquityBook value
$49.9M
$253.3M
Total Assets
$185.5M
$286.0M
Debt / EquityLower = less leverage
1.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FBIO
FBIO
RCAT
RCAT
Q4 25
$79.4M
Q3 25
$86.2M
Q2 25
$74.4M
Q1 25
$91.3M
Q4 24
$57.3M
Q3 24
$58.9M
Q2 24
$76.2M
Q1 24
$83.8M
Total Debt
FBIO
FBIO
RCAT
RCAT
Q4 25
$52.4M
Q3 25
$47.8M
Q2 25
$50.0M
Q1 25
$56.4M
Q4 24
$58.0M
Q3 24
$52.5M
Q2 24
$67.0M
Q1 24
$61.4M
Stockholders' Equity
FBIO
FBIO
RCAT
RCAT
Q4 25
$49.9M
Q3 25
$55.9M
$253.3M
Q2 25
$43.9M
Q1 25
$22.3M
$28.9M
Q4 24
$22.7M
$27.0M
Q3 24
$21.2M
Q2 24
$17.9M
Q1 24
$23.0M
$49.6M
Total Assets
FBIO
FBIO
RCAT
RCAT
Q4 25
$185.5M
Q3 25
$181.4M
$286.0M
Q2 25
$159.9M
Q1 25
$178.1M
$59.7M
Q4 24
$144.2M
$51.1M
Q3 24
$127.1M
Q2 24
$145.7M
Q1 24
$164.6M
$55.3M
Debt / Equity
FBIO
FBIO
RCAT
RCAT
Q4 25
1.05×
Q3 25
0.86×
Q2 25
1.14×
Q1 25
2.53×
Q4 24
2.55×
Q3 24
2.48×
Q2 24
3.75×
Q1 24
2.67×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FBIO
FBIO
RCAT
RCAT
Operating Cash FlowLast quarter
$-12.5M
$-23.9M
Free Cash FlowOCF − Capex
$-24.5M
FCF MarginFCF / Revenue
-254.2%
Capex IntensityCapex / Revenue
6.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-55.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FBIO
FBIO
RCAT
RCAT
Q4 25
$-12.5M
Q3 25
$-6.1M
$-23.9M
Q2 25
$-27.6M
Q1 25
$-19.6M
$-15.9M
Q4 24
$-12.9M
$-10.1M
Q3 24
$-20.1M
Q2 24
$-21.8M
Q1 24
$-25.4M
$-4.1M
Free Cash Flow
FBIO
FBIO
RCAT
RCAT
Q4 25
Q3 25
$-24.5M
Q2 25
Q1 25
$-16.2M
Q4 24
$-10.2M
Q3 24
Q2 24
Q1 24
$-4.2M
FCF Margin
FBIO
FBIO
RCAT
RCAT
Q4 25
Q3 25
-254.2%
Q2 25
Q1 25
-992.9%
Q4 24
Q3 24
Q2 24
Q1 24
-71.1%
Capex Intensity
FBIO
FBIO
RCAT
RCAT
Q4 25
Q3 25
6.9%
Q2 25
Q1 25
16.8%
Q4 24
Q3 24
0.0%
Q2 24
Q1 24
0.8%
Cash Conversion
FBIO
FBIO
RCAT
RCAT
Q4 25
Q3 25
-1.04×
Q2 25
-1.78×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FBIO
FBIO

Segment breakdown not available.

RCAT
RCAT

Products$8.5M88%
Services$1.2M12%

Related Comparisons